Pinometostat has been used in a phase 1 study mainly focused on acute leukemia patients characterized by mixed lineage leukemia (MLL) gene rearrangements [(MLL-r), 11q23 translocations; [126]]. This evidence concerns the gene KMT2A and acute leukemia.